Provided by Tiger Fintech (Singapore) Pte. Ltd.

Corvus Pharmaceuticals

4.35
+0.21505.21%
Volume:557.54K
Turnover:2.40M
Market Cap:279.20M
PE:-4.29
High:4.47
Open:4.05
Low:4.03
Close:4.13
Loading ...

Corvus Pharmaceuticals Tumbles Despite Upbeat Comments From CEO -- Market Talk

Dow Jones
·
19 Dec 2024

Why Is Corvus Pharmaceuticals Stock Trading Lower On Wednesday?

Benzinga
·
19 Dec 2024

Corvus Pharma Says Data From Atopic Dermatitis Study Shows Favorable Safety Profile; Shares Fall Pre-Bell

MT Newswires Live
·
18 Dec 2024

BRIEF-Corvus Pharmaceuticals Announces Interim Data From Phase 1 Trial Of Soquelitinib For Atopic Dermatitis

Reuters
·
18 Dec 2024

Corvus Pharmaceuticals announce interim data from Phase 1 trial of soquelitinib

TIPRANKS
·
18 Dec 2024

Corvus Pharmaceuticals Inc - Lowest Dose Level Cohorts Show Favorable Safety and Efficacy

THOMSON REUTERS
·
18 Dec 2024

Corvus Pharmaceuticals Announces Interim Data From Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

THOMSON REUTERS
·
18 Dec 2024

Corvus Pharmaceuticals Announces Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

GlobeNewswire
·
18 Dec 2024

Why Corvus Pharmaceuticals Shares Are Trading Higher By Around 22%; Here Are 20 Stocks Moving Premarket

Benzinga
·
18 Dec 2024

Stocks to Watch: Worthington Enterprises, Corvus Pharmaceuticals, CommScope Holding

Dow Jones
·
18 Dec 2024

Corvus Pharmaceuticals Shares Rise 14% Ahead of Soquelitinib Trial Data Reveal

Dow Jones
·
18 Dec 2024

BRIEF-Corvus Pharmaceuticals To Announce Interim Data From Placebo-Controlled Phase 1 Clinical Trial Of Soquelitinib For Atopic Dermatitis On December 18, 2024

Reuters
·
18 Dec 2024

Corvus Pharmaceuticals to Announce Interim Data From Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on December 18, 2024

THOMSON REUTERS
·
18 Dec 2024

Corvus Pharmaceuticals to Announce Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on December 18, 2024

GlobeNewswire
·
18 Dec 2024

Individual investors account for 50% of Corvus Pharmaceuticals, Inc.'s (NASDAQ:CRVS) ownership, while private equity firms account for 16%

Simply Wall St.
·
11 Dec 2024

Corvus Pharmaceuticals Says Published Soquelitinib Data Highlights Novel Approach to Immunotherapy

MT Newswires Live
·
05 Dec 2024